LY 2922083

Drug Profile

LY 2922083

Alternative Names: LY2922083

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action FFAR1 protein stimulants; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Singapore (PO, Capsule)
  • 22 Aug 2013 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in Singapore (NCT01748552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top